|
|
Volumn 110, Issue 12, 2015, Pages 1737-1738
|
|
Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease
a
b
b
b
b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
CERTOLIZUMAB PEGOL;
INFLIXIMAB;
MERCAPTOPURINE;
MESALAZINE;
METHOTREXATE;
VEDOLIZUMAB;
GASTROINTESTINAL AGENT;
MONOCLONAL ANTIBODY;
NATALIZUMAB;
TUMOR NECROSIS FACTOR ALPHA;
ADULT;
BLOODY DIARRHEA;
CASE REPORT;
COLON CROHN DISEASE;
COLON ULCER;
CROHN DISEASE;
DEFECATION URGENCY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
ERYTHEMA NODOSUM;
EXUDATE;
HUMAN;
ILEOCOLIC CROHN DISEASE;
INTESTINE MUCOSA;
INTESTINE RESECTION;
LETTER;
MALE;
PRIORITY JOURNAL;
SIGMOIDOSCOPY;
TREATMENT DURATION;
ANTAGONISTS AND INHIBITORS;
COMBINATION DRUG THERAPY;
DRUG ADMINISTRATION;
PATHOLOGY;
REMISSION;
TREATMENT OUTCOME;
ADULT;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CROHN DISEASE;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
GASTROINTESTINAL AGENTS;
HUMANS;
INFLIXIMAB;
MALE;
NATALIZUMAB;
REMISSION INDUCTION;
SIGMOIDOSCOPY;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 84951001359
PISSN: 00029270
EISSN: 15720241
Source Type: Journal
DOI: 10.1038/ajg.2015.355 Document Type: Letter |
|
Times cited : (39)
|
|
References (6)
|
